Celsion Corporation (NASDAQ:CLSN) Stock Jumps 4% in a Week: Here is Why
Celsion Corporation (NASDAQ:CLSN) up 4% in a week. The company has announced preclinical in vivo studies results demonstrating antibodies production and cytotoxic T-cell response to SARS-CoV-2 spike antigen in immunization of BALB/c mice with Celsion’s next-gen PLACCIUNE DNA vaccine. Interestingly the SARS-CoV-2 spike antigen antibodies prevented cultured cells infection in a vital neutralization experiment. Thus, the antibodies production shows PLACCINE’s ability to protect against SARS-CoV-2 exposure, and cytotoxic T-cell response…